GlassScriptPhysician profile
Matthew Snyder Laffer
NPI 1851736763
$151,525.47
in general payments reported to CMS, 2019-2025
37 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $14K · 2021: $34K · 2022: $18K · 2023: $41K · 2024: $11K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $12K · Travel and Lodging: $8,251 · Consulting Fee: $3,450 · Honoraria: $2,250 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,600.00 |
| Food and Beverage | $11,566.71 |
| Travel and Lodging | $8,251.33 |
| Consulting Fee | $3,450.00 |
| Honoraria | $2,250.00 |
| Education | $288.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $105,564.81 | 2019-2025 | |
| Amgen INC. | $25,510.01 | 2019-2025 | Otezla, Otezla, Enbrel |
| Lnhc, INC | $2,412.12 | 2025 | Zelsuvmi |
| Incyte Corporation | $2,330.02 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $2,313.72 | 2022-2025 | Sotyktu |
| Barco, INC. | $1,800.00 | 2021 | |
| Janssen Biotech, INC. | $1,351.05 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,236.88 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,103.60 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Lilly USA, LLC | $1,081.76 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,025.39 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $810.57 | 2020-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $684.81 | 2019-2025 | |
| Dermavant Sciences, INC. | $631.61 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $628.75 | 2019-2025 | Nemluvio |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $568.16 | 2021-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $509.66 | 2019-2025 | Jublia, Duobrii, Siliq |
| Pfizer INC. | $494.44 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $325.63 | 2023-2025 | Zoryve |
| Genentech USA, INC. | $159.71 | 2021-2025 | Xolair |
| Celgene Corporation | $129.59 | 2019 | |
| Mayne Pharma Commercial LLC | $128.52 | 2019-2025 | |
| Organon LLC | $104.31 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $96.33 | 2024-2025 | Xtrac |
| Almirall LLC | $90.05 | 2019-2023 | Klisyri |
| Dermira, INC. | $85.94 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $70.12 | 2020-2021 | |
| Botanix Sb INC | $43.83 | 2025 | Sofdra |
| Dusa Pharmaceuticals, INC. | $39.90 | 2019 | |
| Epi Health, LLC | $39.85 | 2020 | |
| Fresenius Kabi USA, LLC | $33.19 | 2023 | |
| Kyowa Kirin, INC. | $25.85 | 2023 | Poteligeo |
| Biofrontera INC. | $24.93 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.63 | 2024 | Cyltezo |
| Mimedx Group, INC. | $17.78 | 2024 | |
| Oxford Immunotec USA INC | $16.27 | 2022 | |
| Springworks Therapeutics, INC. | $15.68 | 2025 | Gomekli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Laffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.